Cleveland Biolabs
Cleveland BioLabs, Inc. is a biopharmaceutical company focused on developing innovative treatments to activate the immune system and address significant medical challenges, particularly in oncology and radiation protection. Established in 2003 and based in Buffalo, New York, the company utilizes its proprietary platform of toll-like receptor (TLR) activators to create products aimed at mitigating radiation injuries and enhancing cancer therapies. Its lead product candidate, entolimod, serves as an immune-stimulatory agent for both radiation countermeasures and various oncology applications. Additionally, Cleveland BioLabs is developing Mobilan, a recombinant non-replicating adenovirus that targets TLR5. The company collaborates with esteemed institutions such as the Cleveland Clinic and Roswell Park Cancer Institute to advance its research and development initiatives.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Panacela Labs
Series B in 2015
Panacela Labs, Inc. is a biotechnology joint venture founded in 2011, primarily focused on developing innovative gene therapy drugs for the treatment of cancer and infectious diseases. The company aims to enhance cancer treatment through immunotherapy, chemotherapy sensitizers, and specialized therapies targeting prostate cancer. With the goal of improving patient outcomes and promoting healthier lives, Panacela Labs collaborates with various esteemed institutions, including Roswell Park Cancer Institute and Cleveland Clinic Foundation. The company is based in the Innovation Center "Skolkovo" and operates as a subsidiary of Cleveland BioLabs, holding a majority ownership stake.
Panacela Labs
Series A in 2011
Panacela Labs, Inc. is a biotechnology joint venture founded in 2011, primarily focused on developing innovative gene therapy drugs for the treatment of cancer and infectious diseases. The company aims to enhance cancer treatment through immunotherapy, chemotherapy sensitizers, and specialized therapies targeting prostate cancer. With the goal of improving patient outcomes and promoting healthier lives, Panacela Labs collaborates with various esteemed institutions, including Roswell Park Cancer Institute and Cleveland Clinic Foundation. The company is based in the Innovation Center "Skolkovo" and operates as a subsidiary of Cleveland BioLabs, holding a majority ownership stake.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.